|
US20040223966A1
(en)
|
2002-10-25 |
2004-11-11 |
Wolfman Neil M. |
ActRIIB fusion polypeptides and uses therefor
|
|
JP2008507288A
(ja)
|
2004-07-23 |
2008-03-13 |
アクセルロン ファーマ インコーポレーテッド |
ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
|
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
|
US8067562B2
(en)
|
2005-11-01 |
2011-11-29 |
Amgen Inc. |
Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
|
|
BRPI0618947B1
(pt)
|
2005-11-23 |
2022-07-19 |
Acceleron Pharma Inc |
Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea
|
|
US8101564B2
(en)
|
2006-05-03 |
2012-01-24 |
Trustees Of The University Of Pennsylvania |
Methods for regulating osteoclast differentiation and bone resorption using LRRc17
|
|
US8895016B2
(en)
|
2006-12-18 |
2014-11-25 |
Acceleron Pharma, Inc. |
Antagonists of activin-actriia and uses for increasing red blood cell levels
|
|
AU2016250354B2
(en)
|
2006-12-18 |
2019-01-17 |
Acceleron Pharma Inc. |
Activin-ActRII antagonists and uses for increasing red blood cell levels
|
|
CA2672758C
(en)
|
2006-12-18 |
2019-07-30 |
Acceleron Pharma Inc. |
Activin-actrii antagonists and uses for increasing red blood cell levels
|
|
US20100028332A1
(en)
|
2006-12-18 |
2010-02-04 |
Acceleron Pharma Inc. |
Antagonists of actriib and uses for increasing red blood cell levels
|
|
TWI584815B
(zh)
|
2007-02-01 |
2017-06-01 |
艾瑟勒朗法瑪公司 |
活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途
|
|
TW201627320A
(zh)
|
2007-02-02 |
2016-08-01 |
艾瑟勒朗法瑪公司 |
衍生自ＡｃｔＲＩＩＢ的變體與其用途
|
|
MX2009008510A
(es)
|
2007-02-09 |
2010-01-15 |
Acceleron Pharma Inc |
Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer.
|
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
|
US9610327B2
(en)
|
2007-03-06 |
2017-04-04 |
Amgen Inc. |
Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
|
|
TW201718635A
(zh)
|
2007-03-06 |
2017-06-01 |
安美基公司 |
變異之活動素受體多肽及其用途
|
|
WO2009015345A1
(en)
|
2007-07-25 |
2009-01-29 |
Amgen Inc. |
Pharmaceutical compositions comprising fc fusion proteins
|
|
CA2699936A1
(en)
|
2007-09-18 |
2009-03-26 |
Acceleron Pharma Inc. |
Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
|
|
WO2009088572A2
(en)
|
2008-01-07 |
2009-07-16 |
Centocor, Inc. |
Method of treating erythropoietin hyporesponsive anemias
|
|
WO2009111793A2
(en)
|
2008-03-07 |
2009-09-11 |
Myoscience, Inc. |
Subdermal tissue remodeling using myostatin, methods and related systems
|
|
EP2315602A4
(en)
|
2008-06-26 |
2011-11-02 |
Acceleron Pharma Inc |
METHOD OF DOSING AN ACTRIIB ANTAGONIST AND MONITORING TREATED PATIENTS
|
|
KR20110031951A
(ko)
|
2008-06-26 |
2011-03-29 |
악셀레론 파마 인코포레이티드 |
액티빈-ａｃｔｒｉｉａ의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도
|
|
US8216997B2
(en)
|
2008-08-14 |
2012-07-10 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
|
|
DK3750552T5
(da)
|
2008-08-14 |
2024-08-26 |
Acceleron Pharma Inc |
Gdf-fælder
|
|
PE20150680A1
(es)
|
2008-11-26 |
2015-05-16 |
Amgen Inc |
Variantes de polipeptidos receptores de activina iib y aplicaciones de estos
|
|
AU2010204985A1
(en)
|
2009-01-13 |
2011-08-04 |
Acceleron Pharma Inc. |
Methods for increasing adiponectin
|
|
MX355042B
(es)
|
2009-06-08 |
2018-04-02 |
Acceleon Pharma Inc |
Metodos para aumentar adipositos termogenicos.
|
|
CN107267520A
(zh)
|
2009-06-12 |
2017-10-20 |
阿塞勒隆制药公司 |
截短的actriib‑fc融合蛋白
|
|
KR102170682B1
(ko)
|
2009-08-13 |
2020-10-28 |
악셀레론 파마 인코포레이티드 |
적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용
|
|
EP3202459B1
(en)
|
2009-09-09 |
2021-04-14 |
Acceleron Pharma Inc. |
Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content
|
|
EP3260130B1
(en)
|
2009-11-03 |
2021-03-10 |
Acceleron Pharma Inc. |
Methods for treating fatty liver disease
|
|
ES2658292T3
(es)
|
2009-11-17 |
2018-03-09 |
Acceleron Pharma, Inc. |
Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
|
|
WO2012027065A2
(en)
|
2010-08-27 |
2012-03-01 |
Celgene Corporation |
Combination therapy for treatment of disease
|
|
CA2817008A1
(en)
|
2010-11-08 |
2012-05-18 |
Acceleron Pharma Inc. |
Actriia binding agents and uses thereof
|
|
US8501768B2
(en)
|
2011-05-17 |
2013-08-06 |
Hoffmann-La Roche Inc. |
Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
|
|
DK3520805T3
(da)
|
2011-10-17 |
2021-04-19 |
Acceleron Pharma Inc |
Sammensætninger til behandling af myelofibrose
|
|
SMT201800092T1
(it)
|
2011-11-14 |
2018-03-08 |
Regeneron Pharma |
Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a
|
|
GR1007832B
(el)
|
2011-11-21 |
2013-02-14 |
Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, |
Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
|
|
KR101995751B1
(ko)
|
2012-01-05 |
2019-07-03 |
주식회사 와이바이오로직스 |
Ｄｌｋ１ 세포 외 수용성 도메인을 유효성분으로 포함하는 미오스타틴 저해제
|
|
ES2663993T3
(es)
|
2012-05-17 |
2018-04-17 |
Paranta Biosciences Limited |
Uso de folistatina o de un inhibidor de activina para prevenir o tratar la disfunción del injerto de tejido
|
|
JP2015525230A
(ja)
|
2012-06-11 |
2015-09-03 |
アムジエン・インコーポレーテツド |
デュアル受容体アンタゴニスト性抗原結合タンパク質およびその使用
|
|
UA116639C2
(uk)
|
2012-10-09 |
2018-04-25 |
Рег'Юлес Терап'Ютікс Інк. |
Способи лікування синдрому альпорта
|
|
JP6401172B2
(ja)
|
2012-10-24 |
2018-10-10 |
セルジーン コーポレイション |
貧血の治療方法
|
|
WO2014138485A1
(en)
|
2013-03-08 |
2014-09-12 |
Irm Llc |
Ex vivo production of platelets from hematopoietic stem cells and the product thereof
|
|
EA201591825A1
(ru)
|
2013-03-15 |
2016-05-31 |
Амген Инк. |
Антагонизм миостатина у субъектов - людей
|
|
HRP20201914T1
(hr)
|
2013-05-06 |
2021-01-22 |
Scholar Rock, Inc. |
Sastavi i postupci za modulaciju faktora rasta
|
|
WO2015108972A1
(en)
|
2014-01-14 |
2015-07-23 |
Santa Maria Biotherapeutics, Inc. |
Activin inhibitor response prediction and uses for treatment
|
|
JP2017509647A
(ja)
|
2014-03-21 |
2017-04-06 |
アクセルロン ファーマ， インコーポレイテッド |
アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法
|
|
EP3131931B1
(en)
|
2014-04-18 |
2020-10-21 |
Acceleron Pharma Inc. |
Methods for increasing red blood cell levels and treating sickle-cell disease
|
|
CN114699529A
(zh)
|
2014-06-13 |
2022-07-05 |
阿塞勒隆制药公司 |
用于治疗溃疡的方法和组合物
|
|
PE20170471A1
(es)
|
2014-06-13 |
2017-05-14 |
Santa Maria Biotherapeutics Inc |
Polipeptidos receptores formulados y metodos relacionados
|
|
PT3159409T
(pt)
|
2014-06-17 |
2020-01-21 |
Nippon Shinyaku Co Ltd |
Ácido nucleico anti-sentido para utilização no tratamento da distrofia muscular de duchenne
|
|
US10744178B2
(en)
|
2014-08-21 |
2020-08-18 |
Stealth Biotherapeutics Corp |
Methods and compositions for the prevention and treatment of disease
|
|
MA41052A
(fr)
|
2014-10-09 |
2017-08-15 |
Celgene Corp |
Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
|
|
GB201421379D0
(en)
|
2014-12-02 |
2015-01-14 |
Isis Innovation Ltd And Medical Res Council |
Molecule
|
|
EP3227675B1
(en)
|
2014-12-03 |
2023-03-15 |
Celgene Corporation |
Activin-actrii antagonists and uses for treating myelodysplastic syndrome
|
|
US20230142386A1
(en)
|
2014-12-03 |
2023-05-11 |
Celgene Corporation |
Activin-actrii antagonists and uses for treating anemia
|
|
MA41119A
(fr)
|
2014-12-03 |
2017-10-10 |
Acceleron Pharma Inc |
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
|
|
CN113683708A
(zh)
|
2015-04-06 |
2021-11-23 |
阿塞勒隆制药公司 |
单臂i型和ii型受体融合蛋白和其用途
|
|
EP3280435B1
(en)
*
|
2015-04-06 |
2021-06-02 |
Acceleron Pharma Inc. |
Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
|
|
CA2983440C
(en)
*
|
2015-04-22 |
2024-03-12 |
Alivegen Usa Inc. |
Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
|
|
TWI814187B
(zh)
|
2015-05-13 |
2023-09-01 |
美商西建公司 |
使用ACTRII配位體捕捉以治療β-地中海型貧血
|
|
EP3298034A4
(en)
*
|
2015-05-20 |
2019-02-13 |
Celgene Corporation |
IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS
|
|
EP3370754B1
(en)
|
2015-11-04 |
2026-04-29 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating ineffective erythropoiesis
|
|
JP7072507B2
(ja)
|
2015-11-23 |
2022-05-20 |
アクセルロン ファーマ インコーポレイテッド |
眼の障害を処置するための方法
|
|
KR20180128405A
(ko)
|
2016-02-22 |
2018-12-03 |
악셀레론 파마 인코포레이티드 |
면역 활성 증가에 사용하기 위한 ActRII 길항제
|
|
AU2017296040C1
(en)
|
2016-07-15 |
2023-06-22 |
Acceleron Pharma Inc. |
Compositions and methods for treating pulmonary hypertension
|
|
LT3490582T
(lt)
|
2016-07-27 |
2024-07-25 |
Acceleron Pharma Inc. |
Kompozicijos, skirtos naudoti gydant mielofibrozę
|
|
AU2017338916B2
(en)
|
2016-10-05 |
2022-03-24 |
Acceleron Pharma Inc. |
Variant ActRIIB proteins and uses thereof
|
|
CN110678195A
(zh)
|
2016-10-05 |
2020-01-10 |
阿塞勒隆制药公司 |
ALK4:ActRIIB异多聚体及其用途
|
|
WO2018067740A1
(en)
|
2016-10-05 |
2018-04-12 |
Acceleron Pharma, Inc. |
Compositions and method for treating kidney disease
|
|
JOP20190085A1
(ar)
*
|
2016-10-20 |
2019-04-17 |
Biogen Ma Inc |
طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
|
|
CA3043184A1
(en)
|
2016-11-10 |
2018-05-17 |
Keros Therapeutics, Inc. |
Activin receptor type iia variants and methods of use thereof
|
|
US11912750B2
(en)
|
2016-11-10 |
2024-02-27 |
Keros Therapeutics, Inc. |
GDNF fusion polypeptides and methods of use thereof
|
|
GB201620119D0
(en)
|
2016-11-29 |
2017-01-11 |
Pharmafox Therapeutics Ag |
Compounds
|
|
WO2018144542A1
(en)
|
2017-02-01 |
2018-08-09 |
Acceleron Pharma Inc. |
TGFβ AND ACTRII ANTAGONISTS FOR USE IN INCREASING IMMUNE ACTIVITY
|
|
AU2018214629A1
(en)
|
2017-02-06 |
2019-08-22 |
Acceleron Pharma Inc. |
Compositions and methods for treating heart failure
|
|
WO2018231905A1
(en)
|
2017-06-14 |
2018-12-20 |
Celgene Corporation |
Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia
|
|
EP3706777B1
(en)
|
2017-11-09 |
2024-05-22 |
Keros Therapeutics, Inc. |
Activin receptor type iia variants and methods of use thereof
|
|
IL320014A
(en)
|
2018-01-12 |
2025-06-01 |
Keros Therapeutics Inc |
Activin receptor type iib variants and methods of use thereof
|
|
DK3768320T3
(da)
|
2018-03-23 |
2026-08-10 |
Cytoo |
Kombination af alk5-hæmmere og glukokortikoider som induktorer af skeletmuskelhypertrofi
|
|
IL278546B2
(en)
|
2018-05-09 |
2026-03-01 |
Keros Therapeutics Inc |
Activin receptor type IIA variants and methods of using them
|
|
EP3826642B8
(en)
|
2018-07-25 |
2025-06-11 |
Boehringer Ingelheim International GmbH |
Empagliflozin for use in treating alport syndrome
|
|
CA3156007A1
(en)
|
2019-09-27 |
2021-04-01 |
Disc Medicine, Inc. |
METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
|
|
CN115515618A
(zh)
|
2020-03-13 |
2022-12-23 |
阿塞勒隆制药公司 |
用于治疗肾脏疾病或病症的单臂ActRIIA和ActRIIB异多聚体和方法
|
|
WO2021189006A1
(en)
|
2020-03-20 |
2021-09-23 |
Keros Therapeutics, Inc. |
Methods of using activin receptor type iia variants
|
|
EP4121088A4
(en)
|
2020-03-20 |
2024-07-03 |
Keros Therapeutics, Inc. |
Methods of using activin receptor type iib variants
|
|
US20230174620A1
(en)
|
2020-04-28 |
2023-06-08 |
Acceleron Pharma Inc. |
Actrii proteins and use in treating post-capillary pulmonary hypertension
|
|
KR20230026435A
(ko)
|
2020-06-23 |
2023-02-24 |
악셀레론 파마 인코포레이티드 |
Actrii 단백질 및 이의 용도
|
|
EP4674480A3
(en)
*
|
2020-10-02 |
2026-04-08 |
Keros Therapeutics, Inc. |
Methods of using activin receptor type ii variants
|
|
WO2022099166A1
(en)
|
2020-11-09 |
2022-05-12 |
Keros Therapeutics, Inc. |
Methods of treating cardiovascular-related disease
|
|
WO2022235620A1
(en)
|
2021-05-04 |
2022-11-10 |
Keros Therapeutics, Inc. |
Activin receptor type ii chimeras and methods of use thereof
|
|
WO2022271716A2
(en)
|
2021-06-21 |
2022-12-29 |
Keros Therapeutics, Inc. |
Methods of using activin receptor type ii signaling inhibitors
|
|
KR20240049857A
(ko)
|
2021-07-19 |
2024-04-17 |
악셀레론 파마 인코포레이티드 |
Actrii 단백질 및 이의 용도
|
|
EP4387737A4
(en)
|
2021-08-19 |
2025-06-18 |
Keros Therapeutics, Inc. |
METHODS OF USING INHIBITORS OF ACTIVIN RECEPTOR TYPE II SIGNALING
|
|
EP4392137A1
(en)
|
2021-08-27 |
2024-07-03 |
Versanis Bio, Inc. |
Combination therapies
|
|
EP4469489A4
(en)
|
2022-01-28 |
2026-04-08 |
35Pharma Inc |
Type IIB Variants of the Activin Receptor and Their Uses
|
|
WO2024054985A2
(en)
|
2022-09-09 |
2024-03-14 |
Keros Therapeutics, Inc. |
Methods of administering an activin type iib variant
|
|
WO2024102906A2
(en)
|
2022-11-10 |
2024-05-16 |
Keros Therapeutics, Inc. |
Activin receptor type ii chimeras and methods of use thereof
|
|
AU2023407142A1
(en)
|
2022-12-22 |
2025-08-07 |
35Pharma Inc. |
Activin receptor type iib variants and uses thereof
|
|
WO2024238950A1
(en)
|
2023-05-18 |
2024-11-21 |
Keros Therapeutics, Inc. |
Methods of using activin receptor type ii variants
|
|
WO2024238920A1
(en)
|
2023-05-18 |
2024-11-21 |
Keros Therapeutics, Inc. |
Methods of using activin receptor type ii variants
|
|
EP4750798A1
(en)
|
2023-07-26 |
2026-06-03 |
35Pharma Inc. |
Activin receptor type iib variants and uses thereof
|
|
WO2025122830A1
(en)
|
2023-12-08 |
2025-06-12 |
Keros Therapeutics, Inc. |
Methods of using activin receptor type ii signaling inhibitors
|
|
WO2025147483A1
(en)
|
2024-01-02 |
2025-07-10 |
Keros Therapeutics, Inc. |
Methods of using activin receptor type ii chimeras
|